表紙
市場調査レポート

喘息およびCOPD治療薬市場の予測:主要事業者にとっての市場機会

Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies

発行 Visiongain Ltd 商品コード 214196
出版日 ページ情報 英文 309 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.04円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
喘息およびCOPD治療薬市場の予測:主要事業者にとっての市場機会 Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies
出版日: 2015年10月05日 ページ情報: 英文 309 Pages
概要

世界の喘息およびCOPD(慢性閉塞性肺疾患)治療薬市場の収益は2019年に358億7,000万ドルの規模に達する見通しです。その後2025年にかけて高い収益成長を見せると予測されています。世界的な高齢人口の増加と呼吸器系疾患発生率の上昇が売上拡大に貢献する見通しです。

当レポートでは、世界の喘息およびCOPD(慢性閉塞性肺疾患)治療薬の市場について調査し、市場の現状および各種動向、市場規模および市場シェアの推移と予測、主要事業者、主要薬剤、パイプラインの動向などを地域/主要国・薬剤区分別にまとめています。

第1章 本書の概要

第2章 喘息およびCOPD治療薬:イントロダクション

  • 医薬品産業の概要
  • 呼吸器疾患の概要
  • 喘息とは?
    • 有病率の動向
    • 病態生理学
    • 喘息の症状
    • 原因と発症
    • 喘息の治療
    • 治療の指針
    • 薬剤による治療
    • 投与方法
  • COPD(慢性閉塞性肺疾患)とは?
    • 有病率の動向
    • 病態生理学
    • 兆候と症状
    • 治療
    • 薬剤による治療
    • 治療の指針
  • 喘息およびCOPD治療における主な薬剤クラス
    • 気管支拡張剤
      • β2作動薬
      • 抗コリン(作用)薬
    • 抗炎症薬
      • コルチコステロイド剤(ICS)
      • ロイコトリエン受容体拮抗薬
      • 呼吸器疾患治療におけるモノクローナル抗体
    • 配合剤
  • 臨床試験の段階
  • 調査範囲
  • 為替レート

第3章 喘息・COPD治療薬:世界市場の予測

  • 世界の呼吸器関連治療薬市場:治療分野別
  • 世界の喘息・COPD治療薬市場
    • 主要な治療薬
    • 主要事業者
  • 世界の喘息・COPD治療薬市場:治療分野別売上予測
    • 喘息
    • COPD
  • 世界の喘息・COPD治療薬市場:薬剤クラス別売上予測
  • 配合剤が市場をリード
  • 市場シェアの変化の予測
  • 喘息・COPD治療薬:各種動向

第4章 主要国市場の予測

  • 地域別の内訳
  • 地域別予測
  • 国別内訳
  • 国市場予測
  • 米国
  • 日本
  • EU5カ国
  • BRIC諸国
  • メキシコ

第5章 気管支拡張薬による単剤治療の市場

  • 気管支拡張薬による単剤治療:イントロダクション
  • 気管支拡張薬による単剤治療市場
  • 気管支拡張薬による単剤治療:市場予測
  • H薬剤クラスによる市場シェアの変化の予測
  • SABA(Short-Acting Beta2-Agonist)市場の予測
    • 現在の主要SABA
    • SABA:市場予測
    • 主要SABAの市場シェアの予測
    • Ventolin (salbutamol, GSK)
    • ProAir (salbutamol, Teva)
    • Proventil (salbutamol, Merck)
    • Xopenex (levosalbutamol, 大日本住友製薬)
  • LABA(Long-Acting Beta2-Agonist)市場の予測
    • 現在の主要LABA
    • LABA:市場予測
    • 主要LABAの市場シェアの予測
    • Foradil (formoterol, Merck/Novartis)
    • Brovana (arfomoterol, 大日本住友製薬)
    • Arcapta/Onbrez (indacaterol, Novartis)
    • Serevent (salmeterol, GSK)
  • 抗コリン作用薬市場の予測
    • 現在の主要抗コリン作用薬
    • 抗コリン作用薬:市場予測
    • 主要抗コリン作用薬の市場シェアの予測
    • Spiriva (tiotropium, Boehringer Ingelheim)
    • Atrovent (ipratropium, Boehringer Ingelheim)
    • Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Forest/Menarini)

第6章 抗炎症薬市場の予測

  • イントロダクション:抗炎症薬
  • 抗炎症薬市場
  • 主要抗炎症薬の現状
  • 抗炎症薬:市場予測
  • 薬剤クラスによる市場シェアの変化の予測
  • コルチコステロイド市場の予測
    • 主要コルチコステロイドの現状
    • コルチコステロイド:市場予測
    • 主要コルチコステロイドの市場シェアの予測
    • Flixotide/Flovent (fluticasone propionate, GSK)
    • Pulmicort (budesonide, AstraZeneca)
    • QVAR (beclometasone, Teva)
    • Asmanex (mometasone, Merck)
  • 抗ロイコトリエン薬市場の予測
    • 主要抗ロイコトリエン薬の現状
    • 抗ロイコトリエン薬:市場予測
    • Singulair (montelukast, Merck)
  • モノクローナル抗体市場の予測
    • モノクローナル抗体:市場予測
    • Xolair (omalizumab, Novartis/Roche)
    • Cinquil (reslizumab, Teva)
    • Mepolizumab (Bosatria, GSK)
    • Benralizumab (MEDI-563, AstraZeneca/協和発酵キリン)
    • Lebrikizumab (RG3637, Roche)
    • Dupilumab (REGN668, Regeneron/Sanofi)

第7章 配合剤市場の予測

  • イントロダクション:配合剤
  • 配合剤:市場予測
  • 市場シェアの変化の予測
    • Advair/Seretide (fluticasone/salmeterol, GSK)
    • Symbicort (budesonide/formoterol, AstraZeneca)
    • Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
    • Dulera (formoterol/mometasone, Merck)
  • 最近発売された配合剤

第8章 主要企業

  • 激しくなる競合
  • GSK
  • Boehringer Ingelheim
  • AstraZeneca
  • Merck & Co. (Merck)
  • Novartis
  • Roche
  • Teva

第9章 喘息・COPD治療薬のパイプラインの分析・予測

  • 活発な喘息・COPDのパイプライン
  • 気管支拡張薬パイプライン
    • 気管支拡張薬:第3相パイプライン
      • PX1439・PX1442 (Prosonix)
      • PT001 (glycopyrronium, AstraZeneca)
      • Spiriva Respimat (tiotropium, Boehringer Ingelheim)
      • GW642444 (vilanterol, GSK)
      • KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
      • Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
      • QVAR BAI (beclometasone, Teva)
      • Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)
  • 抗炎症薬パイプライン
    • 抗炎症薬:第3相パイプライン
      • PSX1001・PSX1050 (fluticasone propionate pMDI, Prosonix)
      • Masitinib (tyrosine kinase inhibitor, AB Science)
      • Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
      • VR506 (fluticasone propionate DPI, Vectura)
      • Favolir (budesonide, Vectura)
  • 配合剤パイプライン
    • 配合剤:第3相パイプライン
      • PSX2005 (fluticasone/salmeterol, Prosonix)
      • LAS40464 (aclidinium/formoterol, AstraZeneca)
      • PT003 (glycopyrronium/formoterol, AstraZeneca)
      • Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
      • Easyhaler 配合剤 (Orion)
      • VR632 (ICS/LABA, Vectura/Sandoz)
  • その他の喘息・COPD治療薬のパイプライン

第10章 定性分析

  • SWOT分析
  • ポーターのファイブフォース分析;喘息・COPD治療薬市場

第11章 リサーチインタビュー

  • Clive Page氏(Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology, King's College London)
  • 喘息・COPDのパイプライン薬を開発してる企業

第12章 総論

  • 喘息・COPD治療薬:成熟化しつつある市場
  • 世界の喘息・COPD治療薬の市場の現状
  • 世界の喘息・COPD治療薬の市場の予測
  • 喘息・COPD治療薬市場の将来

第13章 用語集

  • 付録A
  • 付録B

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0070

What can be expected from the Asthma and COPD Therapies market? Which areas are going to grow at the fastest rates? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 309-page report provides 260 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and therapies

How will submarkets perform to 2025? Our study forecasts revenues in the following asthma and COPD therapies submarkets:

  • Combination drugs
  • Anti-inflammatory drugs
    • Corticosteroids
    • Anti-Leukotrienes
    • Monoclonal antibodies
    • Other anti-inflammatories
  • Bronchodilator monotherapy
    • Short-acting beta2-agonist (SABAs)
    • Long-acting beta2-agonist (LABAs)
    • Anticholinergics

How will individual therapies perform to 2025? Our study forecasts revenues for 27 therapies including 5 promising pipeline candidates:

  • Ventolin
  • ProAir
  • Proventil
  • Xopenex
  • Foradil
  • Serevent
  • Arcapta/Onbrez
  • Brovana
  • Spiriva
  • Atrovent
  • Eklira/Tudorza/Bretaris
  • Flixotide/Flovent
  • Pulmicort
  • QVAR
  • Asmanex
  • Singulair
  • Xolair
  • Cinquil
  • Mepolizumab
  • Benralizumab
  • Lebrikizumab
  • Dupilumab
  • Advair/Seretide
  • Symbicort
  • Combivent
  • Dulera
  • Breo/Relvar Ellipta

See revenue forecasts for the leading international markets

How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:

  • US
  • Japan
  • EU5
  • BRIC
  • Mexico

Leading companies and potential for market growth

Overall revenue for the Asthma and COPD Therapies market will reach $35.87in 2019, our work forecasts. We predict strong revenue growth through to 2025. An ageing population and increasing incidence of respiratory diseases globally will drive sales to 2025.

Our work analyses the key companies in the market. See visiongain's analysis of 7 leading companies, including these:

  • GSK
  • Boehringer Ingelheim
  • AstraZeneca
  • Merck
  • Novartis
  • Roche
  • Teva

A company profile gives you the following information where available:

  • 10 year revenue forecast for respiratory products with annual growth rates
  • Discussion of a company's activities and outlook
  • Analysis of products currently on the market as well as those in the pipeline

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the Asthma and COPD Therapies industry?

Our new report discusses issues and events affecting the Asthma and COPD Therapies market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of national markets
  • Patent expiry challenging major market players
  • Emerging areas of therapies with potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Asthma and COPD Therapies Market Forecast 2015-2025 report helps you

In summary, our 309-page report gives you the following knowledge:

  • Revenue forecasts to 2025 for the asthma and COPD therapies market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2025 for submarkets and leading therapies in each - discover prospects for leading drugs in the following asthma and COPD submarkets: bronchodilator monotherapy (including SABAs, LABAs and anticholinergics), anti-inflammatory drugs (including corticosteroids, anti-leukotrienes and monoclonal antibodies) and combination drugs
  • Revenue forecasts to 2025 for the leading regional markets - US, Japan, EU5, BRIC and Mexico
  • Assessment of 7leading companies - analysis of respiratory revenues, products and pipeline
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Asthma and COPD therapies market and leading companies. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Asthma and COPD Therapies Market Overview
  • 1.2. Global Asthma and COPD Therapies Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Asthma and COPD Therapies

  • 2.1. The Pharmaceutical Industry: A Very Brief Overview
  • 2.2. Overview of Respiratory Diseases
    • 2.2.1. Classifying Respiratory Diseases: Obstructive and Restrictive
  • 2.3. What Is Asthma?
    • 2.3.1. Trends in Asthma Prevalence
    • 2.3.2. Pathophysiology of Asthma
    • 2.3.3. Symptoms of Asthma
    • 2.3.4. Causes and Triggers for Asthma
    • 2.3.5. Treatment of Asthma
    • 2.3.6. Guidelines for Asthma Treatment
    • 2.3.7. Drug Treatments for Asthma
    • 2.3.8. Drug Delivery Methods in Asthma
  • 2.4. What Is Chronic Obstructive Pulmonary Disease (COPD)?
    • 2.4.1. Trends in COPD Prevalence
    • 2.4.2. Pathophysiology of COPD
    • 2.4.3. Signs and Symptoms of COPD
    • 2.4.4. Treatment of COPD
    • 2.4.5. Drug Treatments for COPD
    • 2.4.6. Guidelines for COPD Treatment
  • 2.5. Major Drug Classes in the Treatment of Asthma and COPD
    • 2.5.1. Bronchodilators
      • 2.5.1.1. Beta2-Agonists
      • 2.5.1.2. Anticholinergics
    • 2.5.2. Anti-Inflammatory Drugs
      • 2.5.2.1. Corticosteroids
      • 2.5.2.2. Leukotriene Receptor Antagonists
      • 2.5.2.3. Monoclonal Antibodies in the Treatment of Respiratory Disease
    • 2.5.3. Combination Drugs
  • 2.6. Phases of Clinical Trials
  • 2.7. Scope of this Report
  • 2.8. Currency Exchange Rates in This Report

3. Asthma and COPD Therapies: World Market 2015-2025

  • 3.1. The World Respiratory Drugs Market by Therapeutic Area
  • 3.2. The World Asthma and COPD Therapies Market in 2014
    • 3.2.1. Leading Asthma and COPD Therapies
    • 3.2.2. Leading Companies in the Asthma and COPD Therapies Market
  • 3.3. World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2015-2025
    • 3.3.1. World Asthma Therapies Market: Sales Forecast 2015-2025
    • 3.3.2. World COPD Therapies Market: Sales Forecast 2015-2025
  • 3.4. World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2015-2025
  • 3.5. Combination Drugs Lead the Asthma and COPD Therapies Market
  • 3.6. How Will Segmental Market Shares Change to 2025?
    • 3.6.1. World Asthma and COPD Therapies Market: Drivers and Restraints 2015-2025
  • 3.7. Asthma and COPD Therapies: Trends and Developments
    • 3.7.1. FDA Requires Replacement of CFC Inhalers with HFA Inhalers
    • 3.7.2. The WISDOM Trial: Will Steroids Lose Their Role in COPD?

4. Leading National Markets 2015-2025

  • 4.1. Regional Breakdown of the World Asthma and COPD Therapies Market
  • 4.2. World Asthma and COPD Therapies Market: Regional Forecast 2015-2025
    • 4.2.1. How Will Regional Market Shares Change to 2025?
  • 4.3. National Breakdown of the World Asthma and COPD Therapies Market
  • 4.4. World Asthma and COPD Therapies Market: National Markets Forecast 2015-2025
    • 4.4.1. How Will National Market Shares Change to 2025?
  • 4.5. The US Asthma and COPD Therapies Market 2015-2025
    • 4.5.1. US Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.5.2. US Asthma and COPD Therapies Market: Trends and Developments
      • 4.5.2.1. Increasing COPD Prevalence in the US
      • 4.5.2.2. FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
      • 4.5.2.3. Pharmacy Benefit Managers Alter Formulary Status of Advair
  • 4.6. Japanese Asthma and COPD Therapies Market 2015-2025
    • 4.6.1. Japanese Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.6.2. Japanese Asthma and COPD Therapies Market: Trends and Developments
      • 4.6.2.1. Generic Penetration to Reach 60% by 2018?
      • 4.6.2.2. Japanese Pharmaceutical Industry Regulatory Reform
  • 4.7. EU5. Asthma and COPD Therapies Market 2015-2025
    • 4.7.1. German Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.7.2. French Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.7.3. UK Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.7.4. Italian Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.7.5. Spanish Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.7.6. EU5 Asthma and COPD Therapies Market: Trends and Developments
      • 4.7.6.1. Germany: Reform of AMNOG Pharmaceutical Rebate Law
      • 4.7.6.2. France: Social Security Finance Bill 2015
      • 4.7.6.3. UK: Improving Asthma and COPD Patient Outcomes
      • 4.7.6.4. Italy: Austerity Measures Limiting Growth
      • 4.7.6.5. Spain: The Start of Recovery in the Spanish Economy
  • 4.8. BRIC Asthma and COPD Therapies Market 2015-2025
    • 4.8.1. Chinese Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.8.2. Chinese Asthma and COPD Therapies Market: Trends and Developments
      • 4.8.2.1. China's Industrial Future and Asthma/COPD
      • 4.8.2.2. Expansion of Healthcare Coverage and Reimbursement
      • 4.8.2.3. Price Controls and the Anhui Model
    • 4.8.3. Brazilian Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.8.4. Brazilian Asthma and COPD Therapies Market: Trends and Developments
      • 4.8.4.1. Increasing Access to Medicines
    • 4.8.5. Indian Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.8.6. Indian Asthma and COPD Therapies Market: Trends and Developments
      • 4.8.6.1. Drug Prices Control Order 2014
      • 4.8.6.2. Expansion of Healthcare Provision
    • 4.8.7. Russian Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.8.8. Russian Asthma and COPD Therapies Market: Trends and Developments
      • 4.8.8.1. No Embargo on Foreign Drug Imports
      • 4.8.8.2. Pharma2020 and the Russian Pharmaceutical Industry
  • 4.9. Mexican Asthma and COPD Therapies Market 2015-2025
    • 4.9.1. Mexican Asthma and COPD Therapies Market Forecast 2015-2025
    • 4.9.2. Mexican Asthma and COPD Therapies Market: Trends and Developments
      • 4.9.2.1. Seguro Popular: Mexican Healthcare Reform
      • 4.9.2.2. COFEPRIS: Regulatory Changes and Improvements
      • 4.9.2.3. Mexico's Agreement for Innovation

5. Bronchodilator Monotherapy Market 2015-2025

  • 5.1. Introduction to Bronchodilator Monotherapy
  • 5.2. The Bronchodilator Monotherapy Market in 2014
    • 5.2.1. Leading Bronchodilators in 2014
  • 5.3. Bronchodilator Monotherapy: Market Forecast 2015-2025
  • 5.4. How Will Market Shares by Drug Class Change to 2025?
  • 5.5. The Short-Acting Beta2-Agonist (SABA) Market 2015-2025
    • 5.5.1. Leading SABAs in 2014
    • 5.5.2. SABAs: Market Forecast 2015-2025
    • 5.5.3. Market Share of Leading SABAs to 2025
    • 5.5.4. Ventolin (salbutamol, GSK)
      • 5.5.4.1. Ventolin: Sales Forecast 2015-2025
    • 5.5.5. ProAir (salbutamol, Teva)
      • 5.5.5.1. ProAir: Sales Forecast 2015-2025
    • 5.5.6. Proventil (salbutamol, Merck)
      • 5.5.6.1. Proventil: Sales Forecast 2015-2025
    • 5.5.7. Xopenex (levosalbutamol, Dainippon Sumitomo)
      • 5.5.7.1. Xopenex: Sales Forecast 2015-2025
  • 5.6. The Long-Acting Beta2-Agonist (LABA) Market 2015-2025
    • 5.6.1. Leading LABAs in 2014
    • 5.6.2. LABAs: Market Forecast 2015-2025
    • 5.6.3. Market Share of Leading LABAs to 2025
    • 5.6.4. Foradil (formoterol, Merck/Novartis)
      • 5.6.4.1. Foradil: Sales Forecast 2015-2025
    • 5.6.5. Brovana (salmeterol, GSK)
      • 5.6.5.1. Brovana: Sales Forecast 2015-2025
    • 5.6.6. Arcapta/Onbrez (indacaterol, Novartis)
      • 5.6.6.1. Arcapta/Onbrez: Sales Forecast 2015-2025
    • 5.6.7. Serevent (arfomoterol, Dainippon Sumitomo)
      • 5.6.7.1. Serevent: Sales Forecast 2015-2025
  • 5.7. The Anticholinergics Market 2015-2025
    • 5.7.1. Leading Anticholinergics in 2014
    • 5.7.2. Anticholinergics: Market Forecast 2015-2025
    • 5.7.3. Market Share of Leading Anticholinergics to 2025
    • 5.7.4. Spiriva (tiotropium, Boehringer Ingelheim)
      • 5.7.4.1. Spiriva: Sales Forecast 2015-2025
    • 5.7.5. Spiriva: Recent Developments
      • 5.7.5.1. Safety Concerns and the UPLIFT Trial
      • 5.7.5.2. Results of the POET Study
      • 5.7.5.3. Competition from Combination Products
    • 5.7.6. Atrovent (ipratropium, Boehringer Ingelheim)
      • 5.7.6.1. Atrovent: Sales Forecast 2015-2025
    • 5.7.7. Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Menarini)
      • 5.7.7.1. Eklira/Tudorza/Bretaris: Sales Forecast 2015-2025

6. Anti-Inflammatory Drugs Market 2015-2025

  • 6.1. Introduction to Anti-Inflammatory Drugs
  • 6.2. The Anti-Inflammatory Drugs Market in 2014
    • 6.2.1. Leading Anti-Inflammatory Drugs in 2014
  • 6.3. Anti-Inflammatory Drugs: Market Forecast 2015-2025
  • 6.4. How Will Market Shares by Drug Class Change to 2025?
  • 6.5. The Corticosteroids Market 2015-2025
    • 6.5.1. Leading Corticosteroids in 2014
    • 6.5.2. Corticosteroids: Market Forecast 2015-2025
    • 6.5.3. Market Share of Leading Corticosteroids to 2025
    • 6.5.4. Flixotide/Flovent (fluticasone propionate, GSK)
      • 6.5.4.1. Flixotide/Flovent: Sales Forecast 2015-2025
    • 6.5.5. Pulmicort (budesonide, AstraZeneca)
      • 6.5.5.1. Pulmicort: Sales Forecast 2015-2025
    • 6.5.6. QVAR (beclometasone, Teva)
      • 6.5.6.1. QVAR: Sales Forecast 2015-2025
    • 6.5.7. Asmanex (mometasone, Merck)
      • 6.5.7.1. Asmanex: Sales Forecast 2015-2025
  • 6.6. The Anti-Leukotrienes Market 2015-2025
    • 6.6.1. Leading Anti-Leukotrienes in 2014
    • 6.6.2. Anti-Leukotrienes: Market Forecast 2015-2025
      • 6.6.2.1. Market Share of Leading Anti-Leukotrienes to 2025
    • 6.6.3. Singulair (montelukast, Merck)
      • 6.6.3.1. Singulair: Sales Forecast 2015-2025
  • 6.7. The Monoclonal Antibodies Market 2015-2025
    • 6.7.1. Monoclonal Antibodies: Market Forecast 2015-2025
      • 6.7.1.1. Market Share of Leading Monoclonal Antibodies to 2025
    • 6.7.2. Xolair (omalizumab, Novartis/Roche)
      • 6.7.2.1. Xolair: Sales Forecast 2015-2025
    • 6.7.3. Cinquil (reslizumab, Teva)
      • 6.7.3.1. Cinquil: Sales Forecast 2015-2025
    • 6.7.4. Mepolizumab (Bosatria, GSK)
      • 6.7.4.1. Mepolizumab: Sales Forecast 2015-2025
    • 6.7.5. Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
      • 6.7.5.1. Benralizumab: Sales Forecast 2015-2025
    • 6.7.6. Lebrikizumab (RG3637, Roche)
      • 6.7.6.1. Lebrikizumab: Sales Forecast 2015-2025
    • 6.7.7. Dupilumab (REGN668, Regeneron/Sanofi)
      • 6.7.7.1. Dupilumab: Sales Forecast 2015-2025

7. Combination Drugs Market 2015-2025

  • 7.1. Introduction to Combination Drugs
    • 7.1.1. Leading Combination Drugs in 2014
  • 7.2. Combination Drugs: Market Forecast 2015-2025
  • 7.3. How Will Market Shares by Drug Change to 2025?
    • 7.3.1. Advair/Seretide (fluticasone/salmeterol, GSK)
      • 7.3.1.1. Advair/Seretide: Sales Forecast 2015-2025
    • 7.3.2. Symbicort (budesonide/formoterol fumarate, AstraZeneca)
      • 7.3.2.1. Symbicort: Sales Forecast 2015-2025
      • 7.3.2.2. Symbicort: The SMART Concept
    • 7.3.3. Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
      • 7.3.3.1. Combivent: Sales Forecast 2015-2025
    • 7.3.4. Dulera (formoterol/mometasone, Merck)
      • 7.3.4.1. Dulera: Sales Forecast 2015-2025
    • 7.3.5. Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
      • 7.3.5.1. Breo/Relvar: Sales Forecast 2015-2025
  • 7.4. Recently Launched Combination Drugs

8. Leading Companies in the Asthma and COPD Therapies Market

  • 8.1. Asthma and COPD Therapies: Increasing Competition
    • 8.1.1. Leading Companies in Asthma and COPD in 2015
    • 8.1.2. Leading Companies: Market Forecast 2015-2025
    • 8.1.3. How Will Leading Companies' Market Shares Change to 2025?
  • 8.2. GSK
    • 8.2.1. GSK: Asthma and COPD Therapies
    • 8.2.2. GSK: Sales Forecast 2015-2025
    • 8.2.3. GSK: Products in Development
    • 8.2.4. GSK: Recent Developments
      • 8.2.4.1. Recently Launched Combination Drugs
      • 8.2.4.2. GSK Divests OTC Products
      • 8.2.4.3. GSK Asset Swap with Novartis to Restructure Consumer Health
      • 8.2.4.4. GSK Presents Data on Eosinophil Levels and COPD
  • 8.3. Boehringer Ingelheim
    • 8.3.1. Boehringer Ingelheim: Asthma and COPD Therapies
    • 8.3.2. Boehringer Ingelheim: Sales Forecast 2015-2025
    • 8.3.3. Boehringer Ingelheim: Asthma and COPD Product Development Ceased
    • 8.3.4. Boehringer Ingelheim: Recent Developments
      • 8.3.4.1. Expansion of Respimat Manufacturing Capacity
      • 8.3.4.2. Respimat Safety Concerns and the TIOSPIR Study
      • 8.3.4.3. Ben Venue Laboratories Shut Down
      • 8.3.4.4. Sale of Roxane Laboratories
  • 8.4. AstraZeneca
    • 8.4.1. AstraZeneca: Asthma and COPD Therapies
    • 8.4.2. AstraZeneca: Sales Forecast 2015-2025
    • 8.4.3. AstraZeneca: Products in Development
    • 8.4.4. AstraZeneca: Recent Developments
      • 8.4.4.1. AstraZeneca Acquires Almirall's Respiratory Portfolio
      • 8.4.4.2. Acquisition of Pearl Therapeutics Expanded AstraZeneca's Combination Drug Pipeline
      • 8.4.4.3. AstraZeneca Rejects Pfizer Takeover Bid
      • 8.4.4.4. AstraZeneca Acquires Right to Actavis' Branded Respiratory Portfolio in US and Canada
  • 8.5. Merck & Co. (Merck)
    • 8.5.1. Merck: Asthma and COPD Therapies
    • 8.5.2. Merck: Sales Forecast 2015-2025
    • 8.5.3. Merck: Products in Development
    • 8.5.4. Merck: Recent Developments
      • 8.5.4.1. Bayer Acquires Merck's Consumer Health Business
      • 8.5.4.2. FDA Rejects Singulair OTC Switch
      • 8.5.4.3. Takeda Ended Co-Promotion of Daxas with Merck
  • 8.6. Novartis
    • 8.6.1. Novartis: Asthma and COPD Therapies
    • 8.6.2. Novartis: Sales Forecast 2015-2025
    • 8.6.3. Novartis: Products in Development
    • 8.6.4. Novartis: Recent Developments
      • 8.6.4.1. Novartis Restructures Following Strategic Review
      • 8.6.4.2. Novartis Presents Data on Ultibro and Seebri
      • 8.6.4.3. Pfizer Promotes Two Novartis COPD drugs in the UK
  • 8.7. Roche
    • 8.7.1. Roche: Asthma and COPD Therapies
    • 8.7.2. Roche: Sales Forecast 2015-2025
    • 8.7.3. Roche: Products in Development
  • 8.8. Teva
    • 8.8.1. Teva: Asthma and COPD Therapies
    • 8.8.2. Teva: Sales Forecast 2015-2025
    • 8.8.3. Teva: Products in Development
    • 8.8.4. Teva: Recent Developments
      • 8.8.4.1. Launch of DuoResp Spiromax

9. Asthma and COPD Therapies Pipeline Analysis 2015-2025

  • 9.1. A Strong Asthma and COPD Pipeline
  • 9.2. The Bronchodilators Pipeline
    • 9.2.1. Bronchodilators: Phase 3 Pipeline
      • 9.2.1.1. PX1439. and PX1442 (Prosonix)
      • 9.2.1.2. PT001. (glycopyrronium, AstraZeneca)
      • 9.2.1.3. Spiriva Respimat (tiotropium, Boehringer Ingelheim)
      • 9.2.1.4. GW642444 (vilanterol, GSK)
      • 9.2.1.5. KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
      • 9.2.1.6. Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
      • 9.2.1.7. QVAR BAI (beclometasone, Teva)
      • 9.2.1.8. Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)
  • 9.3. The Anti-Inflammatory Drugs Pipeline
    • 9.3.1. Anti-Inflammatory Drugs: Phase 3 Pipeline
      • 9.3.1.1. PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
      • 9.3.1.2. Masitinib (tyrosine kinase inhibitor, AB Science)
      • 9.3.1.3. Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
      • 9.3.1.4. VR506 (fluticasone propionate DPI, Vectura)
      • 9.3.1.5. Favolir (budesonide, Vectura)
  • 9.4. The Combination Drugs Pipeline
    • 9.4.1. Combination Drugs: Phase 3 Pipeline
      • 9.4.1.1. PSX2005 (fluticasone/salmeterol, Prosonix)
      • 9.4.1.2. LAS40464 (aclidinium/formoterol, AstraZeneca)
      • 9.4.1.3. PT003 (glycopyrronium/formoterol, AstraZeneca)
      • 9.4.1.4. Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
      • 9.4.1.5. Easyhaler Combination Drugs (Orion)
      • 9.4.1.6. VR632 (ICS/LABA, Vectura/Sandoz)
  • 9.5. Other Asthma and COPD Drugs Pipeline

10. Qualitative Analysis of the Asthma and COPD Therapies Market 2015-2025

  • 10.1. SWOT Analysis of the Asthma and COPD Therapies Market
  • 10.2. Strengths
    • 10.2.1. Increasing Prevalence and Disease Burden
    • 10.2.2. High Costs of Treatment
    • 10.2.3. The Changing Perception of COPD
    • 10.2.4. Patient Education: Understanding the Severity of Respiratory Disease
    • 10.2.5. Lifecycle Management Strategies to Counter Patent Expiry
    • 10.2.6. Advanced Inhaler Technologies to Counter Generic Erosion
    • 10.2.7. Developments in Diagnostics
      • 10.2.7.1. Diagnostic Imaging: Parametric Response Mapping for COPD
      • 10.2.7.2. Biological Markers in COPD
  • 10.3. Weaknesses
    • 10.3.1. Under-Diagnosis: the ‘Ghost Population'
    • 10.3.2. Side-Effects of Drug Classes
    • 10.3.3. Patent Cliff for Devices
    • 10.3.4. Low Patient Adherence
    • 10.3.5. Costing Pressures in both Developed and Emerging Markets
  • 10.4. Opportunities
    • 10.4.1. Patient Phenotyping and Personalised Medicine
    • 10.4.2. A Strong R&D Pipeline
      • 10.4.2.1. Ultra-Long-Acting Beta2-Agonists
      • 10.4.2.2. Muscarinic Antagonists and Beta2-Agonists (MABAs)
      • 10.4.2.3. Monoclonal Antibodies
      • 10.4.2.4. LAMA/LABA Combinations
    • 10.4.3. Opportunities in Telehealth
  • 10.5. Threats
    • 10.5.1. Patent Expiry and Generic Competition
    • 10.5.2. Pharmacy Benefit Managers and Cost Control
    • 10.5.3. The WISDOM Trial Could Reduce Steroid Use in COPD
  • 10.6. Porter's Five Forces Analysis of the Asthma and COPD Therapies Market
    • 10.6.1. Rivalry Among Competitors [Medium]
    • 10.6.2. Threat of New Entrants [Medium]
    • 10.6.3. Power of Suppliers [Medium]
    • 10.6.4. Power of Buyers [High]
    • 10.6.5. Threat of Substitutes [Low]

11. Research Interviews

  • 11.1. Interview with Professor Clive Page, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology, King's College London
    • 11.1.1. Treating Different Phenotypes of Asthma and COPD
    • 11.1.2. Personalised Medicine and Improved Existing Drug Classes
    • 11.1.3. Phenotyping of Asthma/COPD, Diagnosis and Treatment
    • 11.1.4. WISDOM Trial: Questioning the Role of Steroids in COPD
    • 11.1.5. Monoclonal Antibodies in Severe Asthma
    • 11.1.6. Healthcare Costs and the Importance of Prevention
    • 11.1.7. Areas to Improve Diagnosis and Treatment of Asthma
    • 11.1.8. The Importance of Adherence and Early Diagnosis
    • 11.1.9. Developments in Alpha-1 Antitrypsin Deficiency
    • 11.1.10. Other Trends and Developments in Asthma and COPD
  • 11.2. Interview with a Company Developing Pipeline Drugs for Asthma and COPD
    • 11.2.1. Asthma and COPD Treatments in 2014-2024
    • 11.2.2. Personalised Therapies for Asthma and COPD
    • 11.2.3. Drivers and Restraints in the Market
    • 11.2.4. The Outlook for the Asthma and COPD Market

12. Conclusions

  • 12.1. Asthma and COPD Therapies: A Maturing Market
  • 12.2. The World Asthma and COPD Therapies Market in 2014
    • 12.2.1. Current Leading Asthma and COPD Therapies Segments
    • 12.2.2. Leading Asthma and COPD Therapies
    • 12.2.3. Leading Asthma and COPD Therapies Companies
    • 12.2.4. Leading Regional and National Markets
  • 12.3. World Asthma and COPD Therapies Market Forecast 2015-2025
  • 12.4. The Future of the Asthma and COPD Therapies Market?
    • 12.4.1. Growth in Anti-Inflammatory and Combination Drugs
    • 12.4.2. Towards Personalised Medicine
    • 12.4.3. Unmet Needs in Asthma and COPD
    • 12.4.4. Strategies for Growth in 2015-2025

13. Glossary

Appendix A

Appendix B

List of Tables

  • Table 1.1: Asthma and COPD Therapies: Leading National Markets Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014
  • Table 2.1: Classification of Respiratory Diseases, 2015
  • Table 2.2: Causes of Asthma, 2015
  • Table 2.3: Triggers of Asthma, 2015
  • Table 2.4: Clinical Trial Phases
  • Table 2.5: Currency Exchange Rates, 2014
  • Table 3.1: World Respiratory Drugs Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2014
  • Table 3.2: Top 10 Asthma and COPD Therapies: Revenue ($m), 2014
  • Table 3.3: World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 3.4: World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 3.5: World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 3.6: World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2014-2025
  • Table 3.7: Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2014, 2020 and 2025
  • Table 4.1: World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2014
  • Table 4.2: World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2014-2025
  • Table 4.2: World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2014-2025 (continued)
  • Table 4.3: Market Shares (%) of Leading Regional Asthma and COPD Therapies Markets, 2014, 2020 and 2025
  • Table 4.4: World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2014
  • Table 4.5: World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2014-2025
  • Table 4.5: World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2014-2025 (continued)
  • Table 4.6: Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2014, 2020 and 2025
  • Table 4.7: US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.8 : apanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.9 : U5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2014-2025
  • Table 4.10: German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.11: French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.12: UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.13: Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.14: Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.15: BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2014-2025
  • Table 4.16: Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.17: Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.18: Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.19: Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 4.20: Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.1: Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2014
  • Table 5.2: Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2014
  • Table 5.3: Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2014-2025
  • Table 5.4: Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2020 and 2025
  • Table 5.5: Leading SABAs: Revenues ($m) and Market Shares (%), 2014
  • Table 5.6: SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
  • Table 5.7: SABAs Market: Market Shares (%) by Drug, 2014, 2020 and 2025
  • Table 5.8: GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.9: Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.10: Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.11: Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.12: Leading LABAs: Revenues ($m) and Market Shares (%), 2014
  • Table 5.13: LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
  • Table 5.14: LABAs Market: Market Shares (%) by Drug, 2014, 2020 and 2025
  • Table 5.15: Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.16: Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.17: Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.18: GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.20: Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2014
  • Table 5.21: Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
  • Table 5.22: Anticholinergics Market: Market Shares (%) by Drug, 2014, 2020 and 2025
  • Table 5.23: Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.24: Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2014-2024
  • Table 5.25: AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.1: Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2014
  • Table 6.2: Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2014
  • Table 6.3: Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2014-2025
  • Table 6.4: Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2020 and 2025
  • Table 6.5: Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2014
  • Table 6.6: Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
  • Table 6.6: Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025 (continued)
  • Table 6.7: Corticosteroids Market: Market Shares (%) by Drug, 2014, 2020 and 2025
  • Table 6.8: GSK: Flixotide/Flovent Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.9 : straZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.10: Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.11: Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.12: Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2014
  • Table 6.13: Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
  • Table 6.14: Anti-Leukotrienes Market: Market Shares (%) by Drug, 2014, 2020 and 2025
  • Table 6.15: Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.16: Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
  • Table 6.17: Monoclonal Antibodies Market: Market Shares (%) by Drug, 2014, 2020 and 2025
  • Table 6.18: Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.19: Teva: Cinquil Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.20: GSK: Mepolizumab Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.21: AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.22: Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.23: Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 7.1: Leading Combination Drugs: Revenues ($m) and Market Shares (%), 2014
  • Table 7.2: Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
  • Table 7.3: Combination Drugs Market: Market Shares (%) by Drug, 2014, 2020 and 2025
  • Table 7.4: GSK: Advair/Seretide Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 7.5: AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 7.6: Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 7.7: Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 7.8: GSK: Breo/Relvar Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 8.1: Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2014
  • Table 8.2: Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 8.2: Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2014-2025 (continued)
  • Table 8.3: Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2020 and 2025
  • Table 8.4: AstraZeneca: Overview, 2014
  • Table 8.5: AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
  • Table 8.6: AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
  • Table 8.7: AstraZeneca: Asthma and COPD Therapies Pipeline, 2015
  • Table 8.8: Boehringer Ingelheim: Overview, 2014
  • Table 8.9 : oehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
  • Table 8.10: Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
  • Table 8.11: GSK: Overview, 2014
  • Table 8.12: GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
  • Table 8.13: GSK: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
  • Table 8.14: GSK: Asthma and COPD Therapies Pipeline, 2015
  • Table 8.15: Merck: Overview, 2014
  • Table 8.16: Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
  • Table 8.17: Merck: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
  • Table 8.18: Novartis: Overview, 2014
  • Table 8.19: Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
  • Table 8.20: Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
  • Table 8.21: Novartis: Asthma and COPD Therapies Pipeline, 2015
  • Table 8.22: Roche: Overview, 2014
  • Table 8.23: Roche: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
  • Table 8.24: Teva: Overview, 2014
  • Table 8.25: Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
  • Table 8.26: Teva: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
  • Table 8.27: Teva: Asthma and COPD Therapies Pipeline, 2015
  • Table 9.1: Asthma and COPD Drugs Pipeline by Segment, 2015
  • Table 9.2: Bronchodilators Pipeline: Phase 3 Drugs, 2015
  • Table 9.3: Anti-Inflammatory Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 9.4: Combination Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 9.5: Other Asthma and COPD Drugs Pipeline, 2015

List of Figures

  • Figure 1.1: Leading Companies: Asthma and COPD Revenues ($m), 2014
  • Figure 1.2: Global Asthma and COPD Therapies Market Segmentation Overview, 2015
  • Figure 2.1: Summary of GINA Guidance for Asthma Treatment, 2015
  • Figure 2.2: Summary of GOLD Guidance for COPD Treatment, 2015
  • Figure 3.1: World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2014
  • Figure 3.2: World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2014
  • Figure 3.3: Top 10 Asthma and COPD Therapies: Market Shares (%), 2014
  • Figure 3.4: World Asthma and COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 3.5: World Asthma Therapies Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 3.6: World COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 3.7: World Asthma and COPD Therapies Market Forecast: Revenue ($m) by Drug Class, 2014-2025
  • Figure 3.8: World Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2014
  • Figure 3.9: World Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2020
  • Figure 3.10: World Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2025
  • Figure 3.11: World Asthma and COPD Therapies Market: Drivers and Restraints, 2015-2025
  • Figure 4.1: World Asthma and COPD Therapies Market: Revenues ($m) by Region, 2014
  • Figure 4.2: World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2014
  • Figure 4.3: World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2014-2025
  • Figure 4.4: World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2020
  • Figure 4.5: World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2025
  • Figure 4.6: World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2014
  • Figure 4.7: World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2014
  • Figure 4.8: World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2020
  • Figure 4.9: World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2025
  • Figure 4.10: US Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014- 2025
  • Figure 4.11: Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.12: EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2014-2025
  • Figure 4.13: German Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.14: French Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.15: UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and 2014-2025
  • Figure 4.16: Italian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.17: Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.18: BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2014-2025
  • Figure 4.19: Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.20: Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.21: Indian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.22: Russian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.23: Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 5.1: Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2014
  • Figure 5.2: Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2014
  • Figure 5.3: Bronchodilator Monotherapy Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.4: Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2020
  • Figure 5.5: Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2020
  • Figure 5.6: Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2025
  • Figure 5.7: Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2025
  • Figure 5.8: SABAs Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.9: SABAs Market: Market Shares (%) by Drug, 2014
  • Figure 5.10: SABAs Market: Market Shares (%) by Drug, 2020
  • Figure 5.11: SABAs Market: Market Shares (%) by Drug, 2025
  • Figure 5.12: GSK: Ventolin Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.13: Teva: ProAir Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.14: Merck: Proventil Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.15: Dainippon Sumitomo: Xopenex Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.16: LABAs Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.17: LABAs Market: Market Shares (%) by Drug, 2014
  • Figure 5.18: LABAs Market: Market Shares (%) by Drug, 2020
  • Figure 5.19: LABAs Market: Market Shares (%) by Drug, 2025
  • Figure 5.20: Merck/Novartis: Foradil Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.21: Dainippon Sumitomo: Brovana Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.22: Novartis: Arcapta/Onbrez Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.23: GSK: Serevent Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.25: Anticholinergics Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.26: Anticholinergics Market: Market Shares (%) by Drug, 2014
  • Figure 5.27: Anticholinergics Market: Market Shares (%) by Drug, 2020
  • Figure 5.28: Anticholinergics Market: Market Shares (%) by Drug, 2025
  • Figure 5.29: Boehringer Ingelheim: Spiriva Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.30: Boehringer Ingelheim: Atrovent Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.31: AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.1: Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2014
  • Figure 6.2: Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2014
  • Figure 6.3: Anti-Inflammatory Drugs Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.4: Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2020
  • Figure 6.5: Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2020
  • Figure 6.6: Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2025
  • Figure 6.7: Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2025
  • Figure 6.8: Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.9: Corticosteroids Market: Market Shares (%) by Drug, 2014
  • Figure 6.10: Corticosteroids Market: Market Shares (%) by Drug, 2020
  • Figure 6.11: Corticosteroids Market: Market Shares (%) by Drug, 2025
  • Figure 6.12: GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.13: AstraZeneca: Pulmicort Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.14: Teva: QVAR Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.15: Merck: Asmanex Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.16: Anti-Leukotrienes Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.17: Anti-Leukotrienes Market: Market Shares (%) by Drug, 2014
  • Figure 6.18: Anti-Leukotrienes Market: Market Shares (%) by Drug, 2020
  • Figure 6.19: Anti-Leukotrienes Market: Market Shares (%) by Drug, 2025
  • Figure 6.20: Merck: Singulair Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.21: Monoclonal Antibodies Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.22: Monoclonal Antibodies Market: Market Shares (%) by Drug, 2020
  • Figure 6.23: Monoclonal Antibodies Market: Market Shares (%) by Drug, 2025
  • Figure 6.24: Novartis/Roche: Xolair Asthma Indication Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.25: Teva: Cinquil Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.26: GSK: Mepolizumab Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.27: AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.28: Roche: Lebrikizumab Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.29: Regeneron/Sanofi: Dupilumab Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.1: Combination Drugs Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.2: Combination Drugs Market: Market Shares (%) by Drug, 2014
  • Figure 7.3: Combination Drugs Market: Market Shares (%) by Drug, 2020
  • Figure 7.4: Combination Drugs Market: Market Shares (%) by Drug, 2025
  • Figure 7.5: GSK: Advair/Seretide Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.6: AstraZeneca: Symbicort Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.7: Boehringer Ingelheim: Combivent Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.8: Merck: Dulera Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.9: GSK: Breo/Relvar Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.1: Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2014
  • Figure 8.2: Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2014
  • Figure 8.3: Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2020
  • Figure 8.4: Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2020
  • Figure 8.5: Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2025
  • Figure 8.6: Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2025
  • Figure 8.7: AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2014
  • Figure 8.8: AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2014
  • Figure 8.9: AstraZeneca: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.10: Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2014
  • Figure 8.11: Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2014
  • Figure 8.12: Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.13: GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2014
  • Figure 8.14: GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2014
  • Figure 8.15: GSK: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.16: Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2014
  • Figure 8.17: Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2014
  • Figure 8.18: Merck: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.19: Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2014
  • Figure 8.20: Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2014
  • Figure 8.21: Novartis: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.22: Roche: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.23: Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2014
  • Figure 8.24: Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2014
  • Figure 8.25: Teva: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2014-2025
  • Figure 9.1: Asthma and COPD Drugs Pipeline by Segment, 2015
  • Figure 10.1: Asthma and COPD Therapies Market: Strengths and Weaknesses, 2015-2025
  • Figure 10.2: Asthma and COPD Therapies Market: Opportunities and Threats, 2015-2025
  • Figure 10.3: Porter's Five Forces Analysis of the Asthma and COPD Therapies Market, 2015-2025
  • Figure 12.1: World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2014-2025

Companies Listed

  • 3M Drug Delivery Systems
  • AB Science
  • Actavis
  • Alcon
  • Alembic
  • Allen and Hanburys
  • Allergan
  • Almirall
  • Apotex
  • Ario Pharma
  • Array BioPharma
  • Aspen Pharmacare
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Bellephron
  • Ben Vue Laboratories
  • BioWa
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Breath Limited
  • Bristol-Meyer Squibbs
  • Catalent Pharma Solutions
  • Cephalon
  • Ception Therapeutics
  • Chiesi Pharmaceuticals
  • Ciba-Geigy
  • Cipla
  • Circassia Pharmaceuticals
  • CVS Caremark
  • Daewoong Pharmaceutical
  • Dainippon Sumimoto
  • Dr. Reddy's Laboratories
  • Express Scripts
  • Forest Pharmaceuticals
  • Fountain Biopharma
  • Genentech (Roche)
  • Grifols
  • GSK
  • Hikma Pharmaceuticals
  • Ikaria
  • Invion
  • Kamada
  • Kyorin Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lilly
  • Mariposa
  • MedicNova
  • Medimmune
  • Menarini
  • Merck & Co.
  • Mylan
  • Novartis
  • Nycomed
  • Omega Pharma
  • Orion Pharmaceuticals
  • Pearl Therapeutics
  • Perrigo
  • Pfizer
  • Prosonix
  • Reckitt Becnkiser
  • Regeneron
  • Roche
  • Roxane Laboratories
  • Sandoz (Novaris)
  • Sanofi
  • Schering-Plough's
  • SkyePharma
  • Sofotec
  • Stempeutics
  • Sunovion Pharmaceuticals
  • Synairgen
  • Takeda Pharmaceuticals
  • Tanox
  • Teva
  • Theravance
  • Vectura
  • Viatris
  • Watson (Actavis)

Organisations Mentioned In The Report

  • American Lung Association
  • Bank of Spain
  • Bundesministerium fur Gesundheit (German Ministry of Health)
  • Brazilian Unified Health System (SUS)
  • Department of Pharmaceuticals (India)
  • European Lung Foundation
  • European Respiratory Foundation
  • European Respiratory Society
  • Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
  • Global Initiative for Asthma (GINA)
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD)
  • Italian Medicines Agency (AIFA)
  • Italian Servicio Sanitario Nazionale (SSN)
  • Japanese Pharmaceuticals and Medical Devices Agency
  • Pan-American Health Organization (PAHO)
  • Seguro Popular (Mexico)
  • UK National Health Service (NHS)
  • US Centers For Disease Control and Prevention (CDC)
  • US Food and Drug Administration (FDA)
  • US Institutes of Health
  • US National Blood, Heart and Lung Institute
  • World Health Organization (WHO)
Back to Top